Biotech: Page 24
-
Stock via Getty Images
Q&AWinning buy-in from early stage biotech investors
The market is starting to cool down, but with the right strategies, biotechs can still attract early stage financing.
By Taren Grom • Feb. 11, 2022 -
Stock via Getty Images
OpinionIndustry executives on the milestone moments shaping pharma's future
Scientific, technological, and communication changes that are making a permanent impact on the industry.
By Taren Grom • Feb. 9, 2022 -
Explore the Trendline➔
Stock via Getty Images
TrendlineOncology
As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.
By PharmaVoice staff -
Permission granted by Mike Rea.
Q&AInnovation vs. invention
IDEA Pharma’s indices ranks how well companies turn ideas into commercialized pharma products.
By Taren Grom • Feb. 9, 2022 -
Retrieved from Google image.
Q&AGaining real-world results from a decentralized trial
Lark’s principal Investigator OraLee Branch hopes a DCT will lead the company to their true audience.
By Kelly Bilodeau • Feb. 8, 2022 -
Sergio Flores via Getty Images
Home is where the trial is
Facing pandemic disruptions, smaller biotechs are discovering the benefits and challenges of turning to decentralized clinical trials.
By Kelly Bilodeau • Feb. 7, 2022 -
Retrieved from MaxPixel.
Pharma's pain points with AI
Looking beyond the buzz and at the challenges associated with AI.
By Meagan Parrish • Feb. 7, 2022 -
Retrieved from Google image.
OpinionIndustry executives predict the next 'blue oceans' in pharma
Where life science leaders see breakthroughs happening in the industry.
By Taren Grom • Feb. 4, 2022 -
Courtesy of Web Sun
Komodo Health's partnership with Chan Zuckerberg Initiative gives 50 rare disease patient organizations access to next-generation analytics
With 330 million patient healthcare encounters in its database, Komodo assists advocacy organizations in gaining insights on specific patient populations.
By Robin Robinson • Feb. 3, 2022 -
Permission granted by Mary Harmon
Q&APTC's vice president of patient relations outlines the importance of patient input in rare disease R&D
You can't know what matters to rare disease patients unless you ask them.
By Kim Ribbink • Feb. 3, 2022 -
Permission granted by Peter Anastasiou
Q&A // First 90 DaysNew Capsida Biotherapeutics CEO Peter Anastasiou aims to bring AAV therapy to reality
Read what Capsida CEO Peter Anastasiou has planned for his new role.
By Taren Grom • Feb. 3, 2022 -
Pekic via Getty Images
OpinionTalent acquisition stays top of mind for pharma execs
From creating flexible work environments to looking outside the industry for new talent, pharma execs are shifting strategies to keep their teams afloat.
By Taren Grom • Feb. 1, 2022 -
Retrieved from Rare Disease.org.
Q&AFor the CEO of Travere, running a rare disease company is personal
To kick off Rare Disease month, we interview the CEO of Travere Therapeutics
By Kim Ribbink • Feb. 1, 2022 -
Q&A
Foghorn's CEO on why collaborations are key to unlocking precision medicine
With a major development deal under his belt, Adrian Gottschalk is helping the company advance its innovative platform.
By Robin Robinson • Jan. 28, 2022 -
Permission granted by Blueprint Medicines
ProfileTaking the leap and not having all the answers: How incoming CEO Kate Haviland plans to lead Blueprint
For Haviland, success in biotech is about more than drug development.
By Alexandra Pecci • Jan. 28, 2022 -
Ricardo Ceppi via Getty Images
OpinionBiopharma's R&D leaders on how technology can accelerate drug development
How emerging digital tools are providing enhanced clinical insights and improved trial results.
By Taren Grom • Jan. 27, 2022 -
How AI is helping pharma solve some of its COVID problems
With the pressure still on pharma to innovate quickly and go digital, the use-cases for AI are increasing in stride.
By Meagan Parrish • Jan. 25, 2022 -
Permission granted by Craig Lipset
ProfileOne man's quest to boost the patient's role in clinical trials
How a personal diagnosis inspired Craig Lipset to transform patient involvement in medical research.
By Robin Robinson • Jan. 24, 2022 -
Retrieved from Google image.
OpinionLeaders predict improving patient engagement will lead to growth opportunities
Why patient engagement is key to successful business growth.
By Taren Grom • Jan. 24, 2022 -
Retrieved from Google image.
ProfileEvofem CEO Saundra Pelletier aims to level the playing field between men's and women's health
Evofem CEO and PharmaVoice100, Saundra Pelletier, discusses funding challenges for women's health.
By Alexandra Pecci • Jan. 23, 2022 -
Space Frontiers via Getty Images
ProfileVaxxinity looks to pioneer the next revolution in pharma
With a one-of-a-kind platform and novel candidates for major indications, Vaxxinity wants to disrupt the industry’s paradigm of success.
By Meagan Parrish • Jan. 14, 2022 -
Retrieved from Google image.
Opinion
Pharma execs reveal the industry's most pressing issues
Several market factors — including COVID — are driving changes and trends in the industry.
By Taren Grom • Jan. 14, 2022 -
Jack Taylor via Getty Images
Pharma M&A stagnated in 2021 — here's what could help it rebound
There are plenty of reasons pharma could get its M&A groove back in 2022.
By Meagan Parrish • Jan. 13, 2022 -
Diego Camargo/PharmaVoice
Welcome to the new PharmaVoice
A similar mission, a new format, and our plans for PharmaVoice's next chapter.
By Davide Savenije • Jan. 13, 2022 -
Permission granted by Copyright: <a href='https://www.123rf.com/profile_ileezhun'>ileezhun</a>
Biote CEO breaks down barriers in women's health
Women’s health is coming into sharper focus in 2022, but getting funding is still difficult.
By Robin Robinson • Jan. 11, 2022 -
[photo]. Retrieved from Ovid Therapeutics.
Q&AOvid's CEO shares his vision for rare disease developments
Jeremy Levin, chairman and CEO of Ovid Therapeutics discusses the keys to success in rare disease innovation.
By Kim Ribbink • Jan. 10, 2022
Previous
